More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$393558410
EPS
-3.75
P/E ratio
--
Price to sales
148.07
Dividend yield
--
Beta
1.644291
Previous close
$4.79
Today's open
$4.74
Day's range
$4.46 - $4.92
52 week range
$3.95 - $19.11
show more
CEO
Jay Duker
Employees
165
Headquarters
Watertown, MA
Exchange
NASDAQ Global Market
Shares outstanding
86212138
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law Firm
RADNOR, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.
GlobeNewsWire • an hour ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT).
PRNewsWire • Sep 3, 2026

EYEPOINT STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In EyePoint (EYPT) To Contact Him Directly To Discuss Their Options
GlobeNewsWire • Sep 2, 2026

EYPT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving EyePoint Pharmaceuticals
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of EyePoint Pharmaceuticals (“EyePoint” or the “Company”) (NASDAQ: EYPT) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.
GlobeNewsWire • Sep 3, 2026

EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company will participate at the following upcoming conferences:
GlobeNewsWire • Sep 2, 2026

EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
NEW YORK--(BUSINESS WIRE)---- $EYPT #ClassActionLawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of EyePoint Pharmaceuticals (“EyePoint” or the “Company”) (NASDAQ: EYPT) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On August 14, 2026, EyePoint released topline results in its Phase 3 LUGANO wet AMD trial for DURAVYU.
Business Wire • Sep 2, 2026

EYPT ALERT: Investigation Launched into EyePoint, Inc., Investors are Encouraged to Contact KTMC Law Firm
RADNOR, Pa., Aug. 28, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.
PRNewsWire • Aug 28, 2026

EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $EYPT--EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law.
Business Wire • Aug 28, 2026

Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm
RADNOR, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.
GlobeNewsWire • Aug 27, 2026

EyePoint After Lugano: Primary Endpoint Miss, Asymmetric Risk-Reward
EyePoint is rated a speculative strong buy, with a revised fair value of $19 per share, despite increased regulatory risk after LUGANO's primary endpoint miss. LUGANO lowered estimated wet-AMD approval probability to 30%, but its strong durability results reinforced DURAVYU's competitive and commercial potential. LUGANO's primary endpoint miss appears largely driven by unusually unfavorable circumstances, supporting an estimated 70–75% chance that LUCIA meets its primary endpoint.
Seeking Alpha • Aug 27, 2026

¹ Disclosures

Open an M1 investment account to buy and sell EyePoint Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.